PsychRounds: The Psychiatry Podcast

Today, we will discuss GLP-1's and the emerging use of this class of medications in psychiatry. Sources: https://pubmed.ncbi.nlm.nih.gov/42247271/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/ https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2838205 https://pubmed.ncbi.nlm.nih.gov/42070571 https://pubmed.ncbi.nlm.nih.gov/41806782/

We resume our landmark studies series looking at the pivotal study in Major Depressive Disorder (MDD), The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial. References: https://pubmed.ncbi.nlm.nih.gov/12778843/ https://pubmed.ncbi.nlm.nih.gov/19880458/ https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482026 https://pubmed.ncbi.nlm.nih.gov/15061154/ https://pubmed.ncbi.nlm.nih.gov/20370962/ https://pubmed.ncbi.nlm.nih.gov/37491091/

We have a special guest today to talk about one of our favorite topics... dogs! Most people might intuitively say that they feel like their dogs improve their mental health, but today, we look at the science with the leading expert on the subject. Dr. Nancy Gee Profile: https://medschool.vcu.edu/about/portfolio/details/geen2/ References: Dogs Supporting Human Health and Well-Being: A Biopsychosocial Approach: https://pubmed.ncbi.nlm.nih.gov/33860004/ Randomized Controlled Trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC12728353/ , https://pmc.ncbi.nlm.nih.gov/articles/PMC11714157/

Welcome back! Today, we are talking about Simtriyo, which has generated a lot of media attention recently given a newly minted FDA approval for ADHD. References https://pmc.ncbi.nlm.nih.gov/articles/PMC12314114/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12379780/ https://pubmed.ncbi.nlm.nih.gov/31776871/ https://pubmed.ncbi.nlm.nih.gov/40619095/ https://pubmed.ncbi.nlm.nih.gov/28731336/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9426730/

Today we're starting a new type of series - looking at some of the most seminal studies in psychiatry. We're going to start with the CATIE Trial, which was published in 2005. References: https://www.nejm.org/doi/full/10.1056/NEJMoa051688 https://pubmed.ncbi.nlm.nih.gov/19594194/ https://pubmed.ncbi.nlm.nih.gov/17924259/ https://pubmed.ncbi.nlm.nih.gov/17286522/ https://www.nejm.org/doi/full/10.1056/NEJMoa061240 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209844

Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC8924421/ https://www.ncbi.nlm.nih.gov/books/NBK585120/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10177737/

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry. References: Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda docs/label/2015/020717s037s038lbl.pdf Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85. Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642 Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4 Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560 Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119 Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry. References: https://www.ncbi.nlm.nih.gov/books/NBK534811/ https://pubmed.ncbi.nlm.nih.gov/24825644/ https://pubmed.ncbi.nlm.nih.gov/26798982/ https://www.nejm.org/doi/full/10.1056/NEJMct0801733 https://pubmed.ncbi.nlm.nih.gov/26798982/

Welcome back! Today, we will be discussing the placebo effect. References: https://pubmed.ncbi.nlm.nih.gov/16503356/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178 / https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/ https://www.ncbi.nlm.nih.gov/books/NBK548187/ https://pubmed.ncbi.nlm.nih.gov/41626799/

We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair. https://x.com/AllenFrancesMD https://www.amazon.com/stores/author/B001HO76FU https://www.psychiatrictimes.com/authors/allen-frances-md

Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry. References : https://pubmed.ncbi.nlm.nih.gov/21438989/ https://pubmed.ncbi.nlm.nih.gov/18774432/ https://pubmed.ncbi.nlm.nih.gov/25899459/ https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/ https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/ https://pubmed.ncbi.nlm.nih.gov/38706338/ https://pubmed.ncbi.nlm.nih.gov/20207521/

Welcome back, today we are discussing a deceptively difficult topic: What makes something a psychiatric illness? We are joined by our guest Dr. Mark Ruffalo. He is a psychotherapist in private practice in Tampa, FL, and who also serves as Assistant Professor of Psychiatry at the University of Central Florida College of Medicine as well an Adjunct Assistant Professor of Psychiatry at Tufts University School of Medicine. Dr. Ruffalo's Website: https://www.drruffalo.com/ Dr. Ruffalo's LinkedIn: https://www.linkedin.com/in/mark-l-ruffalo-71929063 PRISM: https://www.psychiatrictimes.com/view/use-of-the-prism-diagnostic-instrument-in-clinical-practice PRISM Writing Contest: https://www.psychiatrictimes.com/view/prism-writing-contest-more-on-this-new-diagnostic-tool-from-mark-ruffalo-msw-dpsa

Welcome back! Today we are at the highly prescribed and popular benzodiazepine Lorazepam, also known as Ativan. We look at its uses in psychiatry, especially catatonia. But despite anecdotal efficacy, does the evidence hold up? References: https://www.ncbi.nlm.nih.gov/books/NBK532890/ https://pubmed.ncbi.nlm.nih.gov/36805317/ https://pubmed.ncbi.nlm.nih.gov/6120058/ https://pubmed.ncbi.nlm.nih.gov/10229064/ https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-5899/

Welcome back! Today we are embarking into the first of hopefully several episodes on the importance of vitamins and minerals in mental health. We will specifically be looking at the role of iron deficiency in psychiatry and do an overview on some of the recent research that's been published. References: https://www.ncbi.nlm.nih.gov/books/NBK557376/ https://www.sciencedirect.com/science/article/pii/S0268960X25000827#bb0165 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823909 https://www.sciencedirect.com/science/article/pii/S1389945717315599 https://pubmed.ncbi.nlm.nih.gov/40841680/ https://pubmed.ncbi.nlm.nih.gov/1677067/ https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00463-7/fulltext https://pmc.ncbi.nlm.nih.gov/articles/PMC6139360/

Welcome back! Today our topic is Nutritional Psychiatry and we've invited a special guest - Dr. Laura Lachance, who has done extensive research in the field. Along with Dr. Drew Ramsey, she has published a paper looking at an Antidepressant Food Score or AFS and more recently, she was a part of the EASe-GAD trial, a study looking at the impact of omega-3 fatty acids on anxiety. Antidepressant Food Scale (AFS): https://pubmed.ncbi.nlm.nih.gov/30254980/ EASe-GAD Trial: https://pubmed.ncbi.nlm.nih.gov/39316026/ Gluten and Psychosis: https://pubmed.ncbi.nlm.nih.gov/24368154/ Nutrition Worksheet for Patients: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-021-03575-7 Dr. Lachance's Instagram: https://www.instagram.com/preventivepsychiatry/

Welcome back! Today, we are hosting the highly accomplished Dr. Robert Sapolsky, PHD, a professor of professor of biology, neurology, and neurosurgery at Stanford University. He has had extensive research particularly in the field of neuroendocrinology and chronic stress, which has acted as one of the foundations of modern psychoneuroendocrinology. He is also a research associate at the Institute of Primate Research in Kenya, with over 30 years of field research in Africa. He is also a renowned author, with major works including but not at all limited to Why Zebras Don’t Get Ulcers , Behave: The Biology of Humans at Our Best and Worst , and most recently, Determined: A Science of Life Without Free Will , which challenges us to reconsider free will, morality, and mental health itself through a scientific lens. More about Dr. Sapolsky: https://en.wikipedia.org/wiki/Robert_Sapolsky Dr. Sapolsky's Open Stanford Course: https://www.youtube.com/watch?v=-PpDq1WUtAw&list=PL848F2368C90DDC3D Dr. Sapolsky's Books: https://www.amazon.com/stores/author/B000APOCFE Dr. Sapolsky's Own Podcast: Spotify: https://open.spotify.com/show/0wDrkkznSB8S84kKuK9HCo Apple: https://podcasts.apple.com/us/podcast/robert-sapolsky-father-offspring-interviews/id1782280922

One hundred episodes later, let’s take it back to one of our very first, the Selective Serotonin Reuptake Inhibitors - with a much-needed update. Thank you to our guests, fans, and listeners. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC4428540/ https://pubmed.ncbi.nlm.nih.gov/10333979⁠ ⁠https://pmc.ncbi.nlm.nih.gov/articles/PMC3663330/⁠

Welcome back! Today we have a very special episode on Alprazolam, brand-name Xanax. This benzodiazepine is one of the most commonly-prescribed and sought out psychotropic medications. https://www.ncbi.nlm.nih.gov/books/NBK538165/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6769182/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5846112/ https://pubmed.ncbi.nlm.nih.gov/6141930/ https://pubmed.ncbi.nlm.nih.gov/17514187/